AbCellera Biologics Inc.

Informe acción NasdaqGS:ABCL

Capitalización de mercado: US$1.1b

Salud financiera de hoja de balance de AbCellera Biologics

Salud financiera controles de criterios 6/6

AbCellera Biologics tiene un patrimonio de los accionistas total de $1.2B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.5B y $335.8M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$698.02m
PatrimonioUS$1.13b
Total pasivoUS$333.18m
Activos totalesUS$1.46b

Actualizaciones recientes sobre salud financiera

Recent updates

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

Oct 18

AbCellera Biologics: I Was Wrong

Aug 20

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

Aug 17
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

AbCellera Biologics: A Buy At Current Prices

Aug 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($872.0M) de ABCL superan a sus pasivos a corto plazo ($119.0M).

Pasivo a largo plazo: Los activos a corto plazo de ABCL ($872.0M) superan a sus pasivos a largo plazo ($216.8M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: ABCL está libre de deudas.

Reducción de la deuda: ABCL no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 29.7%.

Cobertura de la deuda: ABCL no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: ABCL no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.


Hoja de balance


Descubre empresas con salud financiera